Compare Stocks: CSLLY, GILD, VRTX, and REGN

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CSLLY CSL	$27.99 +16.9%	$21.12	$16.01 ▼ $37.90	$53.62B	0.57	410,257 shs	37,269 shs
GILD Gilead Sciences	$141.81 +2.1%	$130.33	$108.46 ▼ $157.29	$175.86B	0.32	7.07 million shs	462,535 shs
REGN Regeneron Pharmaceuticals	$813.95 +1.0%	$679.69	$541.00 ▼ $821.11	$83.89B	0.21	848,281 shs	41,342 shs
VRTX Vertex Pharmaceuticals	$520.41 +0.9%	$484.71	$374.17 ▼ $546.17	$132.16B	0.3	1.45 million shs	57,626 shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CSLLY CSL	-0.66%	+0.76%	+10.06%	+37.80%	-72.74%
GILD Gilead Sciences	+0.40%	+4.40%	+3.46%	+6.45%	+17.36%
REGN Regeneron Pharmaceuticals	+0.30%	-0.26%	+19.10%	+27.86%	+38.86%
VRTX Vertex Pharmaceuticals	+1.94%	-1.60%	+6.16%	+18.71%	+31.25%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CSLLY CSL	$27.99 +16.9%	$21.12	$16.01 ▼ $37.90	$53.62B	0.57	410,257 shs	37,269 shs
GILD Gilead Sciences	$141.81 +2.1%	$130.33	$108.46 ▼ $157.29	$175.86B	0.32	7.07 million shs	462,535 shs
REGN Regeneron Pharmaceuticals	$813.95 +1.0%	$679.69	$541.00 ▼ $821.11	$83.89B	0.21	848,281 shs	41,342 shs
VRTX Vertex Pharmaceuticals	$520.41 +0.9%	$484.71	$374.17 ▼ $546.17	$132.16B	0.3	1.45 million shs	57,626 shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CSLLY CSL	-0.66%	+0.76%	+10.06%	+37.80%	-72.74%
GILD Gilead Sciences	+0.40%	+4.40%	+3.46%	+6.45%	+17.36%
REGN Regeneron Pharmaceuticals	+0.30%	-0.26%	+19.10%	+27.86%	+38.86%
VRTX Vertex Pharmaceuticals	+1.94%	-1.60%	+6.16%	+18.71%	+31.25%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CSLLY CSL	2.00	Hold	N/A	N/A
GILD Gilead Sciences	2.83	Moderate Buy	$158.04	11.45% Upside
REGN Regeneron Pharmaceuticals	2.62	Moderate Buy	$801.70	-1.50% Downside
VRTX Vertex Pharmaceuticals	2.92	Moderate Buy	$563.50	8.28% Upside

Current Analyst Ratings Breakdown

Latest CSLLY, GILD, VRTX, and REGN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/17/2026	REGN Regeneron Pharmaceuticals	Leerink Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Market Perform	$641.00 ➝ $824.00
8/11/2026	GILD Gilead Sciences	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy (B-) ➝ Hold (C-)
8/7/2026	CSLLY CSL	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold
8/5/2026	VRTX Vertex Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Buy (B-) ➝ Buy (B)
8/5/2026	VRTX Vertex Pharmaceuticals	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$560.00 ➝ $565.00
8/5/2026	VRTX Vertex Pharmaceuticals	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$615.00 ➝ $617.00
8/5/2026	GILD Gilead Sciences	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Sector Perform	$120.00 ➝ $123.00
8/5/2026	GILD Gilead Sciences	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight	$155.00
8/5/2026	GILD Gilead Sciences	Needham & Company LLC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$170.00
8/4/2026	VRTX Vertex Pharmaceuticals	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$525.00 ➝ $550.00
8/4/2026	VRTX Vertex Pharmaceuticals	Stifel Nicolaus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$500.00

(Data available from 8/18/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CSLLY CSL	$15.56B	3.45	$2.54 per share	11.02	$11.05 per share	2.53
GILD Gilead Sciences	$29.44B	5.97	$10.73 per share	13.22	$18.23 per share	7.78
REGN Regeneron Pharmaceuticals	$14.34B	5.84	$42.53 per share	19.14	$295.66 per share	2.75
VRTX Vertex Pharmaceuticals	$12.59B	10.49	$18.09 per share	28.77	$73.57 per share	7.07

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CSLLY CSL	$3.00B	N/A	N/A	17.72	N/A	N/A	N/A	N/A	N/A
GILD Gilead Sciences	$8.51B	-$2.67	N/A	14.69	N/A	-10.64%	-2.11%	-0.75%	10/29/2026 (Estimated)
REGN Regeneron Pharmaceuticals	$4.50B	$40.46	20.14	16.11	1.37	27.86%	13.47%	10.34%	10/28/2026 (Estimated)
VRTX Vertex Pharmaceuticals	$3.95B	$17.18	30.31	28.10	2.09	35.00%	23.09%	16.72%	11/2/2026 (Estimated)

Latest CSLLY, GILD, VRTX, and REGN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/3/2026	Q2 2026	GILD Gilead Sciences	-$7.25	-$6.75	+$0.50	-$8.45	$7.40 billion	$7.80 billion
8/3/2026	Q2 2026	VRTX Vertex Pharmaceuticals	$4.74	$4.73	-$0.01	$4.31	$3.23 billion	$3.33 billion
7/30/2026	Q2 2026	REGN Regeneron Pharmaceuticals	$10.16	$14.29	+$4.13	$12.23	$3.82 billion	$4.29 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
CSLLY CSL	$0.58	2.07%	N/A	N/A	N/A
GILD Gilead Sciences	$3.28	2.31%	+3.04%	N/A	10 Years
REGN Regeneron Pharmaceuticals	$3.76	0.46%	N/A	9.29%	N/A
VRTX Vertex Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Latest CSLLY, GILD, VRTX, and REGN Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
7/28/2026	GILD Gilead Sciences	quarterly	$0.82	2.43%	9/15/2026	9/15/2026	9/29/2026
7/30/2026	REGN Regeneron Pharmaceuticals	quarterly	$0.94	0.46%	8/18/2026	8/18/2026	8/31/2026

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CSLLY CSL	0.51	2.57	1.15
GILD Gilead Sciences	2.03	1.27	1.09
REGN Regeneron Pharmaceuticals	0.06	3.34	2.78
VRTX Vertex Pharmaceuticals	N/A	3.19	2.74

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CSLLY CSL	0.03%
GILD Gilead Sciences	83.67%
REGN Regeneron Pharmaceuticals	83.31%
VRTX Vertex Pharmaceuticals	90.96%

Insider Ownership

Company	Insider Ownership
CSLLY CSL	N/A
GILD Gilead Sciences	0.30%
REGN Regeneron Pharmaceuticals	6.97%
VRTX Vertex Pharmaceuticals	0.20%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CSLLY CSL	29,904	1.92 billion	N/A	Not Optionable
GILD Gilead Sciences	17,000	1.24 billion	1.24 billion	Optionable
REGN Regeneron Pharmaceuticals	15,410	102.96 million	95.78 million	Optionable
VRTX Vertex Pharmaceuticals	6,400	253.81 million	253.30 million	Optionable

CSLLY, GILD, VRTX, and REGN Headlines

Recent News About These Companies

UNIVEST FINANCIAL Corp Takes Position in Vertex Pharmaceuticals Incorporated $VRTX

3 hours ago | marketbeat.com

Perigon Wealth Management LLC Takes $4.39 Million Position in Vertex Pharmaceuticals Incorporated $VRTX

4 hours ago | marketbeat.com

Mitsubishi UFJ Asset Management Co. Ltd. Acquires New Shares in Vertex Pharmaceuticals Incorporated $VRTX

4 hours ago | marketbeat.com

Citizens Financial Group Inc. RI Purchases New Stake in Vertex Pharmaceuticals Incorporated $VRTX

August 18 at 4:32 AM | marketbeat.com

Cornerstone Advisors LLC Purchases New Position in Vertex Pharmaceuticals Incorporated $VRTX

August 18 at 4:32 AM | marketbeat.com

Grandfield & Dodd LLC Makes New Investment in Vertex Pharmaceuticals Incorporated $VRTX

August 18 at 4:31 AM | marketbeat.com

Deutsche Bank AG Invests $784.39 Million in Vertex Pharmaceuticals Incorporated $VRTX

August 18 at 4:16 AM | marketbeat.com

6,857 Shares in Vertex Pharmaceuticals Incorporated $VRTX Bought by Commerzbank Aktiengesellschaft FI

August 18 at 4:16 AM | marketbeat.com

BlackRock Inc. Invests $11.98 Billion in Vertex Pharmaceuticals Incorporated $VRTX

August 18 at 3:20 AM | marketbeat.com

Vortex Energy Engages Market Maker

August 17 at 8:32 AM | finance.yahoo.com

Plato Investment Management Ltd Purchases Shares of 6,083 Vertex Pharmaceuticals Incorporated $VRTX

August 17 at 6:24 AM | marketbeat.com

2,792 Shares in Vertex Pharmaceuticals Incorporated $VRTX Purchased by Simplicity Wealth LLC

August 17 at 6:16 AM | marketbeat.com

Trivium Point Advisory LLC Takes Position in Vertex Pharmaceuticals Incorporated $VRTX

August 17 at 6:15 AM | marketbeat.com

Nippon Life Global Investors Americas Inc. Makes New $18.99 Million Investment in Vertex Pharmaceuticals Incorporated $VRTX

August 17 at 6:07 AM | marketbeat.com

Flputnam Investment Management Co. Invests $19.93 Million in Vertex Pharmaceuticals Incorporated $VRTX

August 17 at 4:08 AM | marketbeat.com

Global Retirement Partners LLC Purchases New Position in Vertex Pharmaceuticals Incorporated $VRTX

August 17 at 4:08 AM | marketbeat.com

2,486,038 Shares in Vertex Pharmaceuticals Incorporated $VRTX Bought by AIGH Capital Management LLC

August 17 at 3:04 AM | marketbeat.com

S&CO Inc. Buys Shares of 4,103 Vertex Pharmaceuticals Incorporated $VRTX

August 16 at 6:55 AM | marketbeat.com

TFR Capital LLC. Takes Position in Vertex Pharmaceuticals Incorporated $VRTX

August 16 at 6:39 AM | marketbeat.com

125,970 Shares in Vertex Pharmaceuticals Incorporated $VRTX Bought by ABN AMRO Bank N.V.

August 16 at 3:03 AM | marketbeat.com

Is Vertex Pharmaceuticals (VRTX) Fairly Valued As Pipeline Catalysts Near?

August 15 at 7:50 AM | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CSLLY, GILD, VRTX, and REGN Company Descriptions

CSL OTCMKTS:CSLLY

$27.99 +4.04 (+16.87%)

As of 09:47 AM Eastern

CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, Hong Kong, and internationally. The company operates through CSL Behring, CSL Seqirus, and CSL Vifor segments. The CSL Behring segment offers plasma products, gene therapies, and recombinants. The CSL Seqirus segment provides influenza related products and pandemic services to governments. The CSL Vifor segment offers products in the therapeutic areas of iron deficiency and nephrology. The company also licenses CSL intellectual property. CSL Limited was founded in 1916 and is headquartered in Melbourne, Australia.

Gilead Sciences NASDAQ:GILD

$141.80 +2.89 (+2.08%)

As of 10:08 AM Eastern

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. The company has collaboration agreements with Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Arcellx, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company was incorporated in 1987 and is headquartered in Foster City, California.

Regeneron Pharmaceuticals NASDAQ:REGN

$813.94 +8.02 (+0.99%)

As of 10:08 AM Eastern

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration with Mammoth Biosciences, Inc. to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.

Vertex Pharmaceuticals NASDAQ:VRTX

$520.41 +4.86 (+0.94%)

As of 10:08 AM Eastern

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor. The company's pipeline includes VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1 clinical trial; VX-548, a non-opioid medicine for the treatment of acute and neuropathic pain which is in Phase 3 clinical trial; Exa-cel, for the treatment of sickle cell disease and transfusion-dependent beta thalassemia which is in Phase 2/3 clinical trial. In addition, it provides inaxaplin for the treatment of APOL1-mediated focal segmental glomerulosclerosis and co-morbidities, such as hypertension which is in single Phase 2/3; VX- 880 and VX-264, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-970, which is in Phase 2 clinical trial for the treatment of cancer; and VX-803 and VX-984 for treatment of cancer in Phase 1 clinical trial. Further, it sells the products to specialty pharmacy and specialty distributors in the United States, as well as retail pharmacies, hospitals, and clinics. Additionally, the company has collaborations with CRISPR Therapeutics AG.; Moderna, Inc.; Entrada Therapeutics, Inc.; Arbor Biotechnologies, Inc.; Mammoth Biosciences, Inc.; and Verve Therapeutics., as well as collaborations with Tevard Biosciences to develop novel tRNA-based therapies for duchenne muscular dystrophy. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CSLLY, GILD, VRTX, and REGN Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CSLLY, GILD, VRTX, and REGN Earnings

Compare Dividends

Latest CSLLY, GILD, VRTX, and REGN Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CSLLY, GILD, VRTX, and REGN Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

CSLLY, GILD, VRTX, and REGN Company Descriptions

CSL OTCMKTS:CSLLY

Gilead Sciences NASDAQ:GILD

Regeneron Pharmaceuticals NASDAQ:REGN

Vertex Pharmaceuticals NASDAQ:VRTX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CSLLY, GILD, VRTX, and REGN Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CSLLY, GILD, VRTX, and REGN Earnings

Compare Dividends

Latest CSLLY, GILD, VRTX, and REGN Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CSLLY, GILD, VRTX, and REGN Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

CSLLY, GILD, VRTX, and REGN Company Descriptions

CSL OTCMKTS:CSLLY

Gilead Sciences NASDAQ:GILD

Regeneron Pharmaceuticals NASDAQ:REGN

Vertex Pharmaceuticals NASDAQ:VRTX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools